Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neurol Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Overview
Neurol Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neurol Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neurol Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Companies Involved in Therapeutics Development
Assuage Pharmaceuticals Inc
Ctcbio Inc
Jeil Pharmaceutical Co Ltd
Kyung Dong Co Ltd
Sobrera Pharma AB
Sopharma AD
Suven Life Sciences Ltd
Yuhan Corp
Neurol Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Drug Profiles
(varenicline tartrate + bupropion hydrochloride) SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CDFF-0318 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cytisinicline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JLP-1603 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-8001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize CHRNB2 and CHR4 for Psychiatric Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CHRNB2 and CHR4 for Smoking Cessation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-911 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varenicline tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varenicline tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neurol Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Dormant Products
Neurol Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Discontinued Products
Neurol Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Product Development Milestones
Featured News & Press Releases
Jun 08, 2021: Pfizer Cada announces recall of Champix
Jun 03, 2021: Achieve announces allowance of U.S. patents for dosing and administration of Cytisinicline for the treatment and prevention of addiction
Apr 14, 2021: Achieve announces publication of the ORCA-1 phase 2b clinical trial of Cytisinicline in adult smokers in nicotine and tobacco research
Mar 25, 2021: Achieve announces publication of the RAUORA head-to-head non-inferiority clinical trial comparing Cytisinicline and Chantix (varenicline) in addiction
Oct 27, 2020: Achieve Life Sciences to host smoking cessation key opinion leader virtual roundtable
Oct 07, 2020: Achieve Life Sciences announces start of phase 3 ORCA-2 clinical trial evaluating cytisinicline for smoking cessation
Sep 10, 2020: Achieve Life Sciences announces presentation of Cytisinicline data at the 20th Annual Society for Research on Nicotine & Tobacco Europe (SRNT-E) virtual conference
Jul 31, 2020: Achieve announces Patent granted in the U.S. for novel alogs of Cytisinicline for use in CNS and Addiction Indications
Jun 29, 2020: Achieve announces successful results from the investigator-initiated RAUORA head-to-head non-inferiority clinical trial comparing Cytisinicline and Chantix (varenicline) as a treatment to quit smoking
Dec 09, 2019: Achieve Life Sciences announces completion of meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline smoking cessation phase 3 clinical development program
Oct 24, 2019: Achieve Life Sciences announces presentation of Cytisinicline data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Iugural Conference
Sep 30, 2019: Achieve Life Sciences announces completion of maximum tolerated dose study
Sep 13, 2019: Achieve Life Sciences announces fil phase 2b ORCA-1 trial data presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
Sep 05, 2019: Achieve Life Sciences to host investor day on September 20th including roundtable discussion with smoking cessation medical experts and fil data from the phase 2b ORCA-1trial
Jul 23, 2019: Achieve Life Sciences extends collaboration with the tiol Institutes of Health to advance the development of Cytisinicline for Smoking Cessation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Assuage Pharmaceuticals Inc, 2021
Pipeline by Ctcbio Inc, 2021
Pipeline by Jeil Pharmaceutical Co Ltd, 2021
Pipeline by Kyung Dong Co Ltd, 2021
Pipeline by Sobrera Pharma AB, 2021
Pipeline by Sopharma AD, 2021
Pipeline by Suven Life Sciences Ltd, 2021
Pipeline by Yuhan Corp, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021